AACR 2023 | Phase I/II trial of EP0031, a next generation selective RET inhibitor

RET fusions occur in various cancers, and resistance to selpercatinib and pralsetinib, current first generation selective RET inhibitors that are indicated for non-small cell lung cancer and pancreatic cancer, are a growing issue. Vivek Subbiah, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the Phase I/II trial (NCT05265091) of EP0031, a next generation selective RET inhibitor. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.